These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 28716306)

  • 21. A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience.
    Ghisoni E; Katsaros D; Maggiorotto F; Aglietta M; Vaira M; De Simone M; Mittica G; Giannone G; Robella M; Genta S; Lucchino F; Marocco F; Borella F; Valabrega G; Ponzone R
    J Ovarian Res; 2018 May; 11(1):42. PubMed ID: 29843747
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tertiary Cytoreduction for Recurrent Epithelial Ovarian Cancer: a Multicenter Study in Turkey.
    Arvas M; Salihoglu Y; Sal V; Gungor T; Sozen H; Kahramanoglu I; Topuz S; Demirkiran F; Iyibozkurt C; Bese T; Ozgu BS; Vatansever D; Tokgozoglu N; Berkman S; Turan H; Bengisu E; Sofiyeva N; Demiral I; Meydanli M
    Asian Pac J Cancer Prev; 2016; 17(4):1909-15. PubMed ID: 27221875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tertiary cytoreduction in patients with recurrent ovarian carcinoma.
    Leitao MM; Kardos S; Barakat RR; Chi DS
    Gynecol Oncol; 2004 Oct; 95(1):181-8. PubMed ID: 15385129
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns.
    Park JY; Seo SS; Kang S; Lee KB; Lim SY; Choi HS; Park SY
    Gynecol Oncol; 2006 Dec; 103(3):977-84. PubMed ID: 16837030
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation.
    Fotopoulou C; Zang R; Gultekin M; Cibula D; Ayhan A; Liu D; Richter R; Braicu I; Mahner S; Harter P; Trillsch F; Kumar S; Peiretti M; Dowdy SC; Maggioni A; Trope C; Sehouli J
    Ann Surg Oncol; 2013 Apr; 20(4):1348-54. PubMed ID: 23054114
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Surgery in recurrent epithelial ovarian cancer: benefits on Survival for patients with residual disease of 0.1-1 cm after secondary cytoreduction.
    Tian WJ; Jiang R; Cheng X; Tang J; Xing Y; Zang RY
    J Surg Oncol; 2010 Mar; 101(3):244-50. PubMed ID: 20112269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study.
    Deraco M; Virzì S; Iusco DR; Puccio F; Macrì A; Famulari C; Solazzo M; Bonomi S; Grassi A; Baratti D; Kusamura S
    BJOG; 2012 Jun; 119(7):800-9. PubMed ID: 22571746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients.
    Iwase H; Takada T; Iitsuka C; Nomura H; Abe A; Taniguchi T; Takizawa K
    J Gynecol Oncol; 2015 Oct; 26(4):303-10. PubMed ID: 26197771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [How to increase the optimal rate of secondary cytoreductive surgery in recurrent epithelial ovarian cancer].
    Li YF; Li MD; Liu FY; Liu JH; Li JD
    Ai Zheng; 2003 Nov; 22(11):1193-6. PubMed ID: 14613651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer: an updated series.
    Shih KK; Chi DS; Barakat RR; Leitao MM
    Gynecol Oncol; 2010 May; 117(2):330-5. PubMed ID: 20189234
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
    Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
    Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of surgery in the second relapse of epithelial ovarian cancer. Selection criteria, morbidity and survival outcome.
    Oksefjell H; Sandstad B; Tropé C
    Eur J Gynaecol Oncol; 2011; 32(4):369-76. PubMed ID: 21941955
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Role of Quaternary Cytoreduction in Recurrent Epithelial Ovarian Cancer: A Single-center Experience.
    Bacalbaşa N; Balescu I; Dima S; Brasoveanu V; Popescu I
    Anticancer Res; 2015 Jun; 35(6):3519-23. PubMed ID: 26026119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unplanned postoperative intensive care unit admission for ovarian cancer cytoreduction is associated with significant decrease in overall survival.
    Ross MS; Burriss ME; Winger DG; Edwards RP; Courtney-Brooks M; Boisen MM
    Gynecol Oncol; 2018 Aug; 150(2):306-310. PubMed ID: 29929924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial.
    Harter P; du Bois A; Hahmann M; Hasenburg A; Burges A; Loibl S; Gropp M; Huober J; Fink D; Schröder W; Muenstedt K; Schmalfeldt B; Emons G; Pfisterer J; Wollschlaeger K; Meerpohl HG; Breitbach GP; Tanner B; Sehouli J; ;
    Ann Surg Oncol; 2006 Dec; 13(12):1702-10. PubMed ID: 17009163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer.
    Medina-Franco H; Cortés-González R; Lambreton-Hinojosa F; Fimbres-Morales A; Vargas-Siordia JC
    Ann Surg Oncol; 2017 May; 24(5):1330-1335. PubMed ID: 27995454
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is There a Role for Tertiary (TCR) and Quaternary (QCR) Cytoreduction in Recurrent Ovarian Cancer?
    Fanfani F; Fagotti A; Ercoli A; Gallotta V; Chiantera V; Restaino S; Monterossi G; Scambia G
    Anticancer Res; 2015 Dec; 35(12):6951-5. PubMed ID: 26637921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Total rectosigmoidectomy versus partial rectal resection in primary debulking surgery for advanced ovarian cancer.
    Plotti F; Montera R; Aloisi A; Scaletta G; Capriglione S; Luvero D; De Cicco Nardone C; Basile S; Benedetti Panici P; Angioli R
    Eur J Surg Oncol; 2016 Mar; 42(3):383-90. PubMed ID: 26725211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of perioperative β blocker use on patient outcomes after primary cytoreductive surgery in high-grade epithelial ovarian carcinoma.
    Al-Niaimi A; Dickson EL; Albertin C; Karnowski J; Niemi C; Spencer R; Shahzad MM; Uppal S; Saha S; Rice L; Nally AM
    Gynecol Oncol; 2016 Dec; 143(3):521-525. PubMed ID: 27693123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pre-operative serum albumin is associated with post-operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgery.
    Ataseven B; du Bois A; Reinthaller A; Traut A; Heitz F; Aust S; Prader S; Polterauer S; Harter P; Grimm C
    Gynecol Oncol; 2015 Sep; 138(3):560-5. PubMed ID: 26163893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.